Henry E. Pelish, the Chief Scientific Officer of $NUVL, sold 189 shares of the company on 01-06-2026 for an estimated $18,597. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.3% of their shares of this class of stock. Following this trade, they now own 65,888 shares of this class of $NUVL stock.
$NUVL Insider Trading Activity
$NUVL insiders have traded $NUVL stock on the open market 143 times in the past 6 months. Of those trades, 0 have been purchases and 143 have been sales.
Here’s a breakdown of recent trading of $NUVL stock by insiders over the last 6 months:
- JAMES E FLYNN has made 0 purchases and 2 sales selling 742,574 shares for an estimated $70,874,975.
- ALEXANDRA BALCOM (Chief Financial Officer) has made 0 purchases and 34 sales selling 144,501 shares for an estimated $12,955,468.
- JAMES RICHARD PORTER (President and CEO) has made 0 purchases and 21 sales selling 135,433 shares for an estimated $11,508,080.
- DEBORAH ANN MILLER (Chief Legal Officer) has made 0 purchases and 23 sales selling 85,952 shares for an estimated $8,492,939.
- MATTHEW SHAIR has made 0 purchases and 12 sales selling 67,500 shares for an estimated $6,835,738.
- HENRY E. PELISH (Chief Scientific Officer) has made 0 purchases and 18 sales selling 46,305 shares for an estimated $3,994,651.
- DARLENE NOCI (Chief Development Officer) has made 0 purchases and 26 sales selling 31,417 shares for an estimated $2,919,695.
- CHRISTOPHER DURANT TURNER (Chief Medical Officer) has made 0 purchases and 7 sales selling 7,417 shares for an estimated $721,320.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NUVL Hedge Fund Activity
We have seen 98 institutional investors add shares of $NUVL stock to their portfolio, and 91 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC removed 1,447,267 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $125,159,650
- RA CAPITAL MANAGEMENT, L.P. added 1,246,456 shares (+inf%) to their portfolio in Q3 2025, for an estimated $107,793,514
- WELLINGTON MANAGEMENT GROUP LLP added 724,491 shares (+46.0%) to their portfolio in Q3 2025, for an estimated $62,653,981
- JPMORGAN CHASE & CO added 476,822 shares (+39.8%) to their portfolio in Q3 2025, for an estimated $41,235,566
- JANUS HENDERSON GROUP PLC added 406,093 shares (+22.8%) to their portfolio in Q3 2025, for an estimated $35,118,922
- POLAR CAPITAL HOLDINGS PLC added 206,138 shares (+25.3%) to their portfolio in Q3 2025, for an estimated $17,826,814
- PICTET ASSET MANAGEMENT HOLDING SA removed 205,256 shares (-34.8%) from their portfolio in Q3 2025, for an estimated $17,750,538
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NUVL Analyst Ratings
Wall Street analysts have issued reports on $NUVL in the last several months. We have seen 15 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 12/19/2025
- Truist Securities issued a "Buy" rating on 11/24/2025
- Guggenheim issued a "Buy" rating on 11/18/2025
- Baird issued a "Outperform" rating on 11/18/2025
- Goldman Sachs issued a "Buy" rating on 11/18/2025
- Stifel issued a "Buy" rating on 11/17/2025
- Leerink Partners issued a "Outperform" rating on 11/17/2025
To track analyst ratings and price targets for $NUVL, check out Quiver Quantitative's $NUVL forecast page.
$NUVL Price Targets
Multiple analysts have issued price targets for $NUVL recently. We have seen 15 analysts offer price targets for $NUVL in the last 6 months, with a median target of $135.0.
Here are some recent targets:
- Anupam Rama from JP Morgan set a target price of $145.0 on 12/19/2025
- Gregory Renza from Truist Securities set a target price of $140.0 on 11/24/2025
- Brad Canino from Guggenheim set a target price of $155.0 on 11/18/2025
- Colleen Kusy from Baird set a target price of $158.0 on 11/18/2025
- Richard Law from Goldman Sachs set a target price of $135.0 on 11/18/2025
- Andrew Berens from Leerink Partners set a target price of $149.0 on 11/17/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $155.0 on 11/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
